2021
Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry
Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, Tolaney SM, Winer EP, Vallejo CT, Lin NU. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Research And Treatment 2021, 187: 843-852. PMID: 33590387, DOI: 10.1007/s10549-021-06121-x.Peer-Reviewed Original ResearchConceptsRisk of BCSMBreast cancer-specific mortalityStage III breast cancerHR-negative diseaseHR-positive diseaseCancer-specific mortalityBreast cancerLate deathsNodal statusTumor sizeUnknown hormone receptor statusHR-positive tumorsEnd Results registryHormone receptor statusEnd Results (SEER) dataTraditional clinicopathologic factorsCumulative incidence functionGray regressionMethodsUsing SurveillanceAxillary nodesClinicopathologic factorsReceptor statusStage subgroupsPrimary tumorTumor grade
2018
Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer
Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2018, 36: jco.2017.76.003. PMID: 29298117, PMCID: PMC5815405, DOI: 10.1200/jco.2017.76.0033.Peer-Reviewed Original ResearchConceptsMetastatic triple-negative breast cancerTriple-negative breast cancerPrimary triple-negative breast cancerTumor fractionSomatic copy number alterationsCell-free DNABreast cancerSingle tertiary care institutionCopy number alterationsRetrospective cohort studySpecific somatic copy number alterationsTertiary care institutionNovel therapeutic approachesNumber alterationsCfDNA tumor fractionMetastatic survivalPrior chemotherapyTNBC cohortMetastatic settingCohort studyOverall survivalCancer Genome AtlasClinicopathologic factorsWorse survivalPrimary tumor
2017
Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.
Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 316-324. PMID: 28275032, DOI: 10.6004/jnccn.2017.0031.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerDe novo metastatic breast cancerNovo metastatic breast cancerTM testingPET/PET-CTTumor markersBreast cancerPET-CTDisease sitesDana-Farber Cancer InstituteSerum tumor markersTiming of imagingPET-CT scanFrequency of imagingCourse of treatmentPatterns of utilizationAsymptomatic patientsNeurologic symptomsRetrospective cohortClinicopathologic factorsTreatment initiationRadiographic studiesCancer InstitutePatientsTumor subtypes
2016
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)
Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Carey LA, Bernard PS, Nielsen TO, Perou CM, Ellis MJ, Barry WT. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). Npj Breast Cancer 2016, 2: 15023. PMID: 28691057, PMCID: PMC5501351, DOI: 10.1038/npjbcancer.2015.23.Peer-Reviewed Original ResearchIntrinsic subtypesOverall survivalGene signaturePAM50 gene signatureCox proportional hazards modelIntrinsic breast cancer subtypesPAM50 intrinsic subtypesStandard clinicopathologic factorsMultivariable Cox modelTaxane-based chemotherapyTaxane-based therapyEvaluable subsetProportional hazards modelBreast cancer subtypesBreast cancer prognosisClinical validation studyAdjuvant anthracyclinesCALGB 9741Distant recurrenceClinicopathologic factorsPrognostic valueRecurrence scoreImproved outcomesTreatment benefitClinical covariates